![]() | Mitsuru SasakoShow email addressDepartment of Surgery, Yodogawa Christian Hospital, Osaka, Japan. | Department of Surgery, Yodogawa Christian Hospital, 1-7-50, Kunijima, Higashiyodogawa-ku, 533-0024, Osaka, ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Mitsuru Sasako:Expert Impact
Concepts for whichMitsuru Sasakohas direct influence:Gastric cancer,Adjuvant chemotherapy,Lymph node,Total gastrectomy,Neoadjuvant chemotherapy,Advanced gastric cancer,Bone marrow,Early gastric cancer.
Mitsuru Sasako:KOL impact
Concepts related to the work of other authors for whichfor which Mitsuru Sasako has influence:Gastric cancer,Lymph node,Adjuvant chemotherapy,Total gastrectomy,Endoscopic submucosal dissection,Postoperative complications,Stomach neoplasms.
KOL Resume for Mitsuru Sasako
Year | |
---|---|
2022 | Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan. |
2021 | Department of Surgery, Yodogawa Christian Hospital, Osaka, Japan |
2020 | Hyogo College of Medicine, Department of Surgery, Japan. Yodogawa Christian Hospital, Osaka, Japan |
2019 | Division of Upper Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan |
2018 | Department of Multidisciplinary Surgical Oncology, Hyogo College of Medicine, Nishinomiya, Japan |
2017 | Hyogo College of Medicine, Nishinomiya, Japan |
2016 | Upper GI Division, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan |
2015 | Department of Surgery, Hyogo College of Medicine,Hyogo, Japan |
2014 | Department of Upper Gastrointestinal Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, 663-8501, Nishinomiya, Hyogo, Japan |
2013 | Department of Surgery, Hyogo College of Medicine, Hyogo, Honshu 663-8501, Japan |
2012 | Department of Upper Gastrointestinal Surgery, Hyogo College of Medicine, 1-1 Mukogawa-Cho, 663-8501, Nishinomiya, Hyogo, Japan |
2011 | Hyogo College of Medicine, Nishinomiya Graduate School of Medical Sciences, Kumamoto University, Kumamoto From Teikyo University School of Medicine and Gastroenterology Center, International University of Health and Welfare Mita Hospital, Tokyo Gastric Surgery Division, National Cancer Center Hospital, Chuo-ku, Japan |
2010 | Digestive Surgery, Hyogo Medical College, Hyogo, Japan Upper GI Surgery Division, Department of Surgery, Hyogo College of Medicine, Hyogo |
2009 | Gastric Surgery Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, 104-0045, Tokyo, Japan |
2008 | Department of Surgical Oncology, National Cancer Center Hospital, 5‐1‐1 Tsukiji, Chuo‐ku, Tokyo 104‐0045, Japan From the Gastric Surgery Division, National Cancer Center Hospital, Tokyo (M.S., T.S.) Orthopaedic Surgery, Gastrointestinal Oncology, Gastric Surgery, and Clinical Laboratory Divisions, National Cancer Center Hospital Cancer Transcriptome Project, National Cancer Center Research Institute BioBusiness Group, Mitsui Knowledge Industry, Tokyo |
2007 | Department of Surgery, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, 104-0045, Tokyo, Japan National Cancer Center Hospital (M.S.), the Cancer Institute Hospital (T.Y., T.N.), Nihon University School of Medicine (M.F.), University of Tokyo (Y.O.), and Tokyo Metropolitan Komagome Hospital (K.A.) — all in Tokyo |
2006 | National Cancer Center Hospital, Tokyo, Japan. |
Concept | World rank |
---|---|
gastrectomy hospital | #1 |
55 65 cent | #1 |
cáncer gástrico hacia | #1 |
location clinicopathological features | #1 |
patients damy3 | #1 |
longterm survival nogca | #1 |
10 cutoff survival | #1 |
lnmresults | #1 |
ibl curative gastrectomy | #1 |
egc mass screening | #1 |
standard techniques guidelines | #1 |
jcog1507 | #1 |
publication humans stomach | #1 |
leakage postoperative stenosis | #1 |
16 introduction | #1 |
dissection gastric | #1 |
survival distal gastrectomy | #1 |
lymphadenectomy european | #1 |
confirm modified | #1 |
complications pprc | #1 |
dissection local control | #1 |
jcog1002 docetaxel | #1 |
large difference survival | #1 |
society gastric | #1 |
scrp3 pprc | #1 |
fgf9 mediator | #1 |
birdie | #1 |
abscess gastrectomy | #1 |
complications criteria | #1 |
odg japan | #1 |
cutoff values scrp3 | #1 |
cardia subcardia | #1 |
serosal invasion difference | #1 |
randomized odg | #1 |
clinical stage ladg | #1 |
pancreatectomy relative risk | #1 |
jcog0110 study | #1 |
pprc damy1 | #1 |
nct00149266 | #1 |
ct34 tumors | #1 |
materials neoplasms tomography | #1 |
gastrectomy terms | #1 |
gastrectomy humans dissection | #1 |
cancerassociated fibroblasts mediator | #1 |
it0116 | #1 |
gastrectomy pancreas complications | #1 |
odg proportion | #1 |
curable gastric | #1 |
analyses patient population | #1 |
gastrectomy operation time | #1 |
Sign-in to see all concepts, it's free! | |
Prominent publications by Mitsuru Sasako
BACKGROUND: Chemotherapy is the standard of care for incurable advanced gastric cancer. Whether the addition of gastrectomy to chemotherapy improves survival for patients with advanced gastric cancer with a single non-curable factor remains controversial. We aimed to investigate the superiority of gastrectomy followed by chemotherapy versus chemotherapy alone with respect to overall survival in these patients.
METHODS: We did an open-label, randomised, phase 3 trial at 44 centres or ...
Known for Gastrectomy Chemotherapy | Advanced Gastric | Single Noncurable Factor | 95 Patients | Phase 3 |
BACKGROUND: We investigated the superiority of docetaxel plus cisplatin and S-1 compared with cisplatin and S-1 in chemotherapy-naive patients with advanced gastric cancer.
METHODS: In this open-label, phase 3, randomised controlled trial, patients were recruited from 56 hospitals in Japan. We enrolled individuals aged 20-75 years who had unresectable or recurrent gastric cancer, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, had received no previous ...
Known for Advanced Gastric Cancer | S1 Cisplatin | Phase 3 | Adjuvant Chemotherapy | Aged Neoplasm |
We evaluated the significance of aberrant DNA methyltransferase 1 (DNMT1) protein expression during gastric carcinogenesis. The protein expression of DNMT1, Muc2, human gastric mucin, E-cadherin, and proliferating cell nuclear antigen was examined immunohistochemically in gastric cancers and corresponding noncancerous mucosae from 134 patients. The DNA methylation status of the CpG islands of the p16, human MutL homologue 1 (hMLH1), E-cadherin, and thrombospondin-1 (THBS-1) genes and the ...
Known for Cpg Islands | Gastric Cancers | Protein Expression | Dna Hypermethylation | Ebv Infection |
PURPOSE: Using multiple genetic markers, including cancer stem-like cells, we evaluated the clinical significance of circulating tumor cells (CTCs) as a prognostic factor for overall survival (OS) and disease-free survival (DFS) in the peripheral blood (PB) of patients with colorectal cancer (CRC) who had undergone curative surgery.
PATIENTS AND METHODS: In a multi-institutional study, 735 patients with CRC were assigned to a retrospective training set (n = 420) or prospective validation ...
Known for Peripheral Blood | Clinical Significance | Colorectal Cancer | Ck Cd133 | Dukes Stage |
BackgroundGastric cancer with extensive lymph node metastasis is commonly considered unresectable, with a poor prognosis. We previously reported the results of the use of cisplatin and S-1 as preoperative chemotherapy for gastric cancer with extensive lymph node metastasis; docetaxel, cisplatin, and S-1 (DCS) have now been investigated for the same purpose.MethodsPatients received two or three 28-day cycles of DCS therapy (docetaxel at 40 mg/m2 and cisplatin at 60 mg/m2 on day 1, S-1 at ...
Known for Preoperative Chemotherapy | Lymph Node | Gastric Cancer | Cisplatin S1 | Dcs Therapy |
BACKGROUND: Locally advanced gastric cancer with extensive regional and/or para-aortic lymph node (PAN) metastases is typically unresectable and associated with poor outcomes. This study investigated the safety and efficacy of S-1 plus cisplatin followed by extended surgery with PAN dissection for gastric cancer with extensive lymph node metastasis.
METHODS: Patients with gastric cancer with bulky lymph node metastasis along the coeliac artery and its branches and/or PAN metastasis ...
Known for Lymph Node | Gastric Cancer | Pan Dissection | Neoadjuvant Chemotherapy | S1 Cisplatin |
Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma
[ PUBLICATION ]
BACKGROUND: Lymph node status is a major determinant of disease recurrence after patients undergo curative resection for gastric carcinoma. A proportion of patients without lymph node metastasis develop systemic recurrences. Recent studies in a range of solid tumors have found a high incidence of micrometastases in the regional lymph nodes of patients with apparently negative lymph nodes. In patients with breast and colorectal carcinoma, the presence of micrometastases has been ...
Known for Gastric Carcinoma | Patients Micrometastases | Lymph Nodes | Immunohistochemically Detected | Node Metastasis |
BackgroundSome patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line treatment for advanced/metastatic gastric cancer. It is controversial as to whether the same treatment strategy can be applied for patients who develop recurrence after adjuvant chemotherapy and those who did not receive adjuvant chemotherapy. To investigate this issue, we ...
Known for Adjuvant Chemotherapy | Gastric Cancer | Recurrence Patients | Exploratory Analysis | Aged Neoplasm |
BackgroundsNo confirmatory randomized controlled trials (RCTs) have evaluated the efficacy of laparoscopy-assisted distal gastrectomy (LADG) compared with open distal gastrectomy (ODG). We performed an RCT to confirm that LADG is not inferior to ODG in efficacy.MethodsWe conducted a multi-institutional RCT. Eligibility criteria included histologically proven gastric adenocarcinoma in the middle or lower third of the stomach, clinical stage I tumor. Patients were preoperatively randomized ...
Known for Ladg Odg | Surgical Outcomes | Distal Gastrectomy | Nodal Dissection | Clinical Stage |
BACKGROUND: Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer.
METHODS: Patients in Japan with stage II or III gastric cancer who underwent gastrectomy with extended (D2) lymph-node dissection were randomly assigned to undergo surgery followed by adjuvant therapy with S-1 or to undergo surgery only. In the S-1 group, administration of S-1 was started within 6 weeks after surgery ...
Known for Oral Fluoropyrimidine | Adjuvant Chemotherapy | Gastric Cancer | Surgery S1 | 1 Year |
BACKGROUND: The usefulness of preoperative oral antibiotics for the prevention of surgical site infection in elective colorectal surgery remains controversial.
OBJECTIVE: This study aimed to investigate the effects of oral antimicrobial prophylaxis in addition to intravenous antimicrobial prophylaxis on patients with ulcerative colitis undergoing restorative proctocolectomy.
DESIGN: This study was a randomized, nonblinded, single-center clinical trial.
SETTING: This study was conducted ...
Known for Surgical Site Infection | Ulcerative Colitis | Oral Antibiotics | Antimicrobial Prophylaxis | Intravenous Administration |
BACKGROUND: The incidence of adenocarcinoma of the gastric cardia has increased recently in the West. However, in Japan, most patients with gastric carcinoma have disease that is situated in the body and the distal stomach. The objectives of this study were to compare the clinicopathologic findings of patients with early gastric carcinoma (EGC) arising at the cardia and those with carcinoma in more distal parts of the stomach, then comparing the findings with those from patients with ...
Known for Gastric Cardia | Patients Egc | Barrett Esophagus | Distal Stomach | Body Mass Bmi |
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
[ PUBLICATION ]
BACKGROUND: Historical data and recent studies show that standardised extended (D2) lymphadenectomy leads to better results than standardised limited (D1) lymphadenectomy. Based on these findings, the Dutch D1D2 trial, a nationwide prospectively randomised clinical trial, was undertaken to compare D2 with D1 lymphadenectomy in patients with resectable primary adenocarcinoma of the stomach. The aim of the study was to assess the effect of D2 compared with D1 surgery on disease recurrence ...
Known for Surgical Treatment | Gastric Cancer | D1 Lymphadenectomy Patients | Curative Intent | Year Follow |
Treatment of early gastric cancer in the elderly patient: results of EMR and gastrectomy at a national referral center in Japan
[ PUBLICATION ]
BACKGROUND: The Japanese population is rapidly aging, and the actual number of elderly patients with gastric cancer, including early cancer, has been increasing, even though the standardized incidence of gastric cancer in the population is decreasing. The optimal treatment for these patients remains a challenge to the surgeon. The aim of this retrospective analysis was to describe the results of gastrectomy and EMR for early gastric cancer in elderly patients (80 years of age and ...
Known for Gastric Cancer | Elderly Patient | Emr Gastrectomy | Tumor Size | Treatment Early |